ArticleNeurourology and urodynamics2013
Battery explantation after sacral neuromodulation in the Medicare population.
Article in Neurourology and urodynamics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Predictive Factors in Sacral Neuromodulation: A Systematic Review.Urologia internationalis · 2022Pooled it
- Reprogramming Sacral Neuromodulation for Sub-Optimal Outcomes: Evidence and Recommendations for Clinical Practice.Neuromodulation : journal of the International Neuromodulation Society · 2021Pooled it
- Programming Algorithms for Sacral Neuromodulation: Clinical Practice and Evidence-Recommendations for Day-to-Day Practice.Neuromodulation : journal of the International Neuromodulation Society · 2020Pooled it
- Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.European urology · 2018Trial
- Predictors of implantable pulse generator placement after sacral neuromodulation: who does better?Neuromodulation : journal of the International Neuromodulation Society · 2014Trial
- Long-Term Outcomes of Sacral Neuromodulation Explantation: A 12-Year Experience at a High-Volume Tertiary Center.Neurourology and urodynamics · 2026Article
- Revision and Explantation After Permanent Sacral Neuromodulation for Overactive Bladder: A Systematic Review and Meta-Analysis.International urogynecology journal · 2026Review
- Identification of Perioperative Risk Factors for Early Sacral Nerve Stimulator Explantation: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Device-Related Reoperations 8 Years Following Sacral Neuromodulation Implantation in Older Women.International urogynecology journal · 2024Article
- Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance.Applied health economics and health policy · 2022Review
- Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder.Translational andrology and urology · 2021Article
- Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Urinary Incontinence in Older Adults: A Translational Research Agenda for a Complex Geriatric Syndrome.Journal of the American Geriatrics Society · 2018Review
- CUA guideline on adult overactive bladder.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017Article
- Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment.International urogynecology journal · 2014Article
- Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder.Female pelvic medicine & reconstructive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
aimsTo determine sacral neuromodulation battery life and the patient and provider risk factors for early explantation in a population-based sample.
methodsA 5% sample of Medicare beneficiaries from 1997 to 2007 served as the data source. All patients who had a sacral neuromodulation device implanted in that time period were included. Variables included in a multivariate analysis of risk factors for removal included gender, age, race, diagnosis, type of test phase, provider specialty, and volume. The number of device reprogramming events was also recorded in this time period.
resultsMean follow-up was 60.5 months. Patients on average had 2.15 reprogramming episodes in their first year, with that number decreasing over subsequent years. Out of the 558 batteries implanted 63 (11.3%) were explanted. Of the 19 implanted individuals who carried the diagnosis of interstitial cystitis (IC), 11 (57.9%) had the battery removed. This was the only variable that predicted early removal, with an odds ratio of explantation of 10.5 (95% CI: 3.9-28.4).
conclusionVery few sacral neuromodulation batteries, once implanted, are removed prematurely. Patients with IC, however, are at very high risk of requiring premature battery removal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.